Biossil Inc.

21 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Oct 2027

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Apr 6, 2027
The maintenance fee for Methods for Treatment of Diseases (US 9,149,483) comes due Apr 6, 2027. Unpaid by Oct 6, 2027, it lapses early.
1 fee due May 28, 2027
The maintenance fee for Methods for Treatment of Diseases (US 11,826,373) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
2 fees due Jun 1 to 3, 2027 · next Jun 1
1 fee due Sep 24, 2027
The maintenance fee for Pentaaza Macrocyclic Ring Complexes Possessing Oral Bioavailability (US 10,597,415) comes due Sep 24, 2027. Unpaid by Mar 24, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

2 of the patents on this record were granted since Aug 16, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 9,642,861	Methods of Treating Oral Mucositis In force Term ends Oct 12, 2027 · High confidence	In force	Term ends Oct 12, 2027	High confidence
US 9,855,279	Methods of Treating Oral Mucositis In force Term ends Oct 12, 2027 · High confidence	In force	Term ends Oct 12, 2027	High confidence
US 10,610,533	Methods of Treating Oral Mucositis In force Term ends Oct 12, 2027 · High confidence	In force	Term ends Oct 12, 2027	High confidence
US 11,612,608	Methods of Treating Oral Mucositis In force Term ends Oct 12, 2027 · High confidence	In force	Term ends Oct 12, 2027	High confidence
US 9,198,893	Combination Antitumor Therapy In force Term ends Jun 20, 2030 · High confidence	In force	Term ends Jun 20, 2030	High confidence
US 8,518,896	Treatment of cancers of the blood using selected glycomimetic compounds In force Term ends Nov 16, 2030 · From the USPTO record	In force	Term ends Nov 16, 2030	From the USPTO record
US 9,149,483	Methods for Treatment of Diseases In force Term ends Sep 24, 2032 · High confidence	In force	Term ends Sep 24, 2032	High confidence
US 10,137,133	Methods for Treatment of Diseases In force Term ends Sep 24, 2032 · High confidence	In force	Term ends Sep 24, 2032	High confidence
US 10,493,081	Methods for Treatment of Diseases In force Term ends Sep 24, 2032 · High confidence	In force	Term ends Sep 24, 2032	High confidence
US 11,826,373	Methods for Treatment of Diseases In force Term ends Sep 24, 2032 · High confidence	In force	Term ends Sep 24, 2032	High confidence

10 of 21 patents shown.

Pro members see all 21.

Pro members: see all 21 patents

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro